Skip to main content

Artidis ends successful study

| News

Artidis ends successful study

26.06.2020

Artidis, a startup from Basel, has developed a nanotechnology platform that can be used for cancer diagnosis, among other things. The platform has now been tested in a study that was able to achieve its primary endpoint.

The team of Artidis, a spin-off from the University of Basel (img: Artidis)

Artidis has developed an innovative nanomechanical biomarker for cancer diagnosis and therapeutic optimization using the company’s own platform. By merging various medical data, the platform aims to make diagnosis quicker and create personalized plans for cancer treatment. This platform and therefore also the biomarker have recently been investigated in the NANO study according to a press release from Artidis, with the primary endpoint of the study being met.

The endpoint was sensitivity, which is a percentage showing the number patients for whom a disease was actually recognized. The primary endpoint of the NANO study was 90 percent, and a value of 96 percent was achieved. As such, the study endpoint was met, meaning that the nanomechanical biomarkers can be used for breast cancer biopsy in a clinical setting. The data from 520 patients were gathered in the analysis.

Marija Plodinec, CEO of Artidis, is quoted in the article: “We are very pleased with the excellent results from this first prospective study conducted in Switzerland.” With this having proven the clinical benefit of the nanomechanical biomarker, she goes on to add: “We are convinced that this brings us one step closer to providing patients undergoing a biopsy procedure with a same day diagnosis.”

Artidis is a spin-off from a research group at the University of Basel and the Swiss Nanoscience Institute. Artidis has already taken part in the Venture Mentoring Program run by the investment and innovation promotion agency Basel Area Business & Innovation. The NANO study was conducted at the University Hospital Basel Breast Care Centre and the University of Basel Biozentrum.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.